Welcome to LookChem.com Sign In|Join Free

CAS

  • or

94-93-9

Post Buying Request

94-93-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

94-93-9 Usage

Uses

Different sources of media describe the Uses of 94-93-9 differently. You can refer to the following data:
1. In histochemistry to detect antigens.
2. N,N′-Bis(salicylidene)ethylenediamine (salen) immobilized on surfactant-coated alumina has been used as complexing agent for on-line preconcentration of copper and lead by flow injection-flame atomic absorption spectrometry (FI-AAS).

Definition

A green fluorescent compound.

General Description

N,N′-Bis(salicylidene)ethylenediamine (salen) reacts with ferric chloride in acetone solution to yield the complex (Fe salen Cl).

Check Digit Verification of cas no

The CAS Registry Mumber 94-93-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 4 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 94-93:
(4*9)+(3*4)+(2*9)+(1*3)=69
69 % 10 = 9
So 94-93-9 is a valid CAS Registry Number.

94-93-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (H0199)  N,N'-Bis(salicylidene)ethylenediamine  >99.0%(T)

  • 94-93-9

  • 25g

  • 355.00CNY

  • Detail
  • TCI America

  • (H0199)  N,N'-Bis(salicylidene)ethylenediamine  >99.0%(T)

  • 94-93-9

  • 500g

  • 3,320.00CNY

  • Detail
  • Alfa Aesar

  • (A13885)  N,N'-Bis(salicylidene)ethylenediamine, 98%   

  • 94-93-9

  • 25g

  • 597.0CNY

  • Detail
  • Alfa Aesar

  • (A13885)  N,N'-Bis(salicylidene)ethylenediamine, 98%   

  • 94-93-9

  • 100g

  • 1065.0CNY

  • Detail
  • Alfa Aesar

  • (A13885)  N,N'-Bis(salicylidene)ethylenediamine, 98%   

  • 94-93-9

  • 500g

  • 4390.0CNY

  • Detail
  • Aldrich

  • (236071)  N,N′-Bis(salicylidene)ethylenediamine  98%

  • 94-93-9

  • 236071-10G

  • 490.23CNY

  • Detail

94-93-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,2'-((Ethane-1,2-diylbis(azanylylidene))bis(methanylylidene))diphenol

1.2 Other means of identification

Product number -
Other names N,N'-BIS(SALICYLIDENE)ETHYLENEDIAMINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:94-93-9 SDS

94-93-9Synthetic route

salicylaldehyde
90-02-8

salicylaldehyde

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol at 20℃; for 1h;100%
In ethanol at 20℃; for 4h; Reflux;100%
In methanol at 20℃;99%
ethylenediamine
107-15-3

ethylenediamine

salicylic acid
69-72-7

salicylic acid

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol for 1h; Reflux; Inert atmosphere;99.6%
2-methyl-benzyl alcohol
89-95-2

2-methyl-benzyl alcohol

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
for 0.0111111h; microwave irradiation;98%
In benzene Heating;92%
In benzene for 3h; Heating;85%
salicylic alcohol
90-01-7

salicylic alcohol

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Stage #1: ethylenediamine In ethanol at 20℃; Green chemistry;
Stage #2: salicylic alcohol With oxygen In ethanol at 20℃; under 760.051 Torr; for 1.46667h; Catalytic behavior; Green chemistry;
95%
With oxygen In toluene at 90℃; Sealed tube;79%
o-hydroxyacetophenone
118-93-4

o-hydroxyacetophenone

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol Reflux;86%
3-acetylcoumarin
3949-36-8

3-acetylcoumarin

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol for 24h; Ambient temperature;55%
N-(4-bromophenyl)-2-oxo-2H-chromene-3-carboxamide
74555-99-0

N-(4-bromophenyl)-2-oxo-2H-chromene-3-carboxamide

ethylenediamine
107-15-3

ethylenediamine

A

N-(2-Amino-ethyl)-N'-(4-bromo-phenyl)-malonamide
74556-05-1

N-(2-Amino-ethyl)-N'-(4-bromo-phenyl)-malonamide

B

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol for 0.5h; Heating;A 30%
B 35%
coumarin-3-carboxy-(4-bromo-3-methyl)-anilide
74556-01-7

coumarin-3-carboxy-(4-bromo-3-methyl)-anilide

ethylenediamine
107-15-3

ethylenediamine

A

N-(2-Amino-ethyl)-N'-(4-bromo-3-methyl-phenyl)-malonamide

N-(2-Amino-ethyl)-N'-(4-bromo-3-methyl-phenyl)-malonamide

B

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol for 0.5h; Heating;A 32%
B 35%
N,N'-bis(salicylidene)-1,2-ethylenediamine zinc

N,N'-bis(salicylidene)-1,2-ethylenediamine zinc

acetic acid
64-19-7

acetic acid

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

N,N'-disalicyliden-ethylenediamine; magnesium salt

N,N'-disalicyliden-ethylenediamine; magnesium salt

acetic acid
64-19-7

acetic acid

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

ethylenediamine
107-15-3

ethylenediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol
2-bromo-1-salicylideneaminoethane
80622-20-4

2-bromo-1-salicylideneaminoethane

ammonia
7664-41-7

ammonia

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

salen

salen

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Kinetics; UV-irradiation;
salicylaldehyde
90-02-8

salicylaldehyde

2-chloro-benzenediazonium-(1)-chloride

2-chloro-benzenediazonium-(1)-chloride

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 28 percent / 33percent aq. NH3 / ethanol / 1.) 1 h, r.t., 2.) heating on the water-bath, 30 min
2: 55 percent / ethanol / 24 h / Ambient temperature
View Scheme
ethyl coumarin-3-carboxylate
1846-76-0

ethyl coumarin-3-carboxylate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Multi-step reaction with 2 steps
2: 35 percent / ethanol / 0.5 h / Heating
View Scheme
N-phenyl-2-oxochromene-3-carboxamide
54396-25-7

N-phenyl-2-oxochromene-3-carboxamide

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Br2 / CHCl3 / Heating
2: 35 percent / ethanol / 0.5 h / Heating
View Scheme
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
1846-99-7

N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Br2 / CHCl3 / Heating
2: 35 percent / ethanol / 0.5 h / Heating
View Scheme
N,N'-disalicylidene-1,6-hexanediamine
4081-35-0

N,N'-disalicylidene-1,6-hexanediamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: chloroform-d1 / 1 h / UV-irradiation
2: ethanol / 3 h / Reflux
View Scheme
Zn(salen)
14167-22-7

Zn(salen)

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With adenosine diphosphate tetrabutylammonium salt In dimethylsulfoxide-d6
With sodium pyrophosphate In dimethyl sulfoxide pH=7.4; Reagent/catalyst;
salicylaldehyde
90-02-8

salicylaldehyde

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In deuteromethanol
(μ-oxo)bis[(1,2-ethanediamino-N,N'-bis(salicylidene))iron(III)]
18601-34-8

(μ-oxo)bis[(1,2-ethanediamino-N,N'-bis(salicylidene))iron(III)]

deferoxamine mesylate
138-14-7

deferoxamine mesylate

A

ferrioxamine B
14836-73-8

ferrioxamine B

B

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With sodium chloride In water Concentration;
4-(Diethylamino)salicylaldehyde
17754-90-4

4-(Diethylamino)salicylaldehyde

diethylamine
109-89-7

diethylamine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
In ethanol for 24h; Reflux;
[FeIII(salen)(H2O)]NO3

[FeIII(salen)(H2O)]NO3

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With sodium pyrophosphate In dimethyl sulfoxide for 0.0833333h; pH=7.4; Reagent/catalyst;
[FeIII(salen)(H2O)]NO3

[FeIII(salen)(H2O)]NO3

A

salicylaldehyde
90-02-8

salicylaldehyde

B

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With sodium pyrophosphate; water In dimethyl sulfoxide for 1.33333h; pH=7.4; Reagent/catalyst;
trans-[MnII(salen)(H2O)2]

trans-[MnII(salen)(H2O)2]

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With phenylphosphonate In dimethyl sulfoxide for 0.0333333h; pH=7.4; Reagent/catalyst; Inert atmosphere;
trans-[MnII(salen)(H2O)2]

trans-[MnII(salen)(H2O)2]

A

salicylaldehyde
90-02-8

salicylaldehyde

B

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Conditions
ConditionsYield
With water In dimethyl sulfoxide for 0.0666667h; pH=7.4; Inert atmosphere;
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

(μ-oxo)bis[(1,2-ethanediamino-N,N'-bis(salicylidene))iron(III)]
18601-34-8

(μ-oxo)bis[(1,2-ethanediamino-N,N'-bis(salicylidene))iron(III)]

Conditions
ConditionsYield
In acetonitrile at 20℃; for 1.3h; Electrochemical reaction; Inert atmosphere;99%
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

N,N'-bis(2-hydroxybenzyl)ethylenediamine
18653-98-0

N,N'-bis(2-hydroxybenzyl)ethylenediamine

Conditions
ConditionsYield
With sodium tetrahydroborate In dichloromethane98%
With sodium tetrahydroborate98%
With sodium tetrahydroborate In ethanol at 20℃; Reflux;91%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

dichloromethane
75-09-2

dichloromethane

3-fluorophenol
372-20-3

3-fluorophenol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(3-fluorophenolato)2]*0.25CH2Cl2

[Ti(N,N’-ethylenebis(salicylideneiminate))(3-fluorophenolato)2]*0.25CH2Cl2

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;97%
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide
35948-25-5

9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide

C40H34N2O6P2
1166187-91-2

C40H34N2O6P2

Conditions
ConditionsYield
In ethanol at 20℃; for 12h;96.7%
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

2-bromo-1,3-2-dioxaphospholane

2-bromo-1,3-2-dioxaphospholane

1,1-ethylenedioxy-3,4,11,12-dibenzo-6-aza-9-ammonium-2,13-dioxa-1-phospha[8.3.0(1,10)]tridecatri-3,5,11-ene bromide

1,1-ethylenedioxy-3,4,11,12-dibenzo-6-aza-9-ammonium-2,13-dioxa-1-phospha[8.3.0(1,10)]tridecatri-3,5,11-ene bromide

Conditions
ConditionsYield
In dichloromethane for 4h;96%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

ortho-cresol
95-48-7

ortho-cresol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(2-methylphenolato)2]

[Ti(N,N’-ethylenebis(salicylideneiminate))(2-methylphenolato)2]

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;94%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

4-Fluorophenol
371-41-5

4-Fluorophenol

dichloromethane
75-09-2

dichloromethane

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-fluorophenolato)2]*0.375CH2Cl2

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-fluorophenolato)2]*0.375CH2Cl2

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;93%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

4-nitro-phenol
100-02-7

4-nitro-phenol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-nitrophenolato)2]

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-nitrophenolato)2]

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;93%
nickel
7440-02-0

nickel

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

nickel(II) salen
14167-20-5, 1160066-31-8

nickel(II) salen

Conditions
ConditionsYield
With tetrabutylammonium tetrafluoroborate In water; acetonitrile at 20℃; for 1.5h; Electrochemical reaction;91%
manganese(II) chloride tetrahydrate

manganese(II) chloride tetrahydrate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

C16H14N2O2(2-)*Mn(3+)*Cl(1-)*2H2O

C16H14N2O2(2-)*Mn(3+)*Cl(1-)*2H2O

Conditions
ConditionsYield
In ethanol90%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

dichloromethane
75-09-2

dichloromethane

2-fluorophenol
367-12-4

2-fluorophenol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(2-fluorophenolato)2]*0.25CH2Cl2

[Ti(N,N’-ethylenebis(salicylideneiminate))(2-fluorophenolato)2]*0.25CH2Cl2

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;89%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

hexane
110-54-3

hexane

3,5-bis-(trifluoromethyl)phenol
349-58-6

3,5-bis-(trifluoromethyl)phenol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(3,5-bis(trifluoromethyl)phenolate)2]*0.375C6H14

[Ti(N,N’-ethylenebis(salicylideneiminate))(3,5-bis(trifluoromethyl)phenolate)2]*0.375C6H14

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;89%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

phenol
108-95-2

phenol

Ti(OPh)2(N,N'-ethylenebis(salicylideneiminate))
216670-23-4

Ti(OPh)2(N,N'-ethylenebis(salicylideneiminate))

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;89%
bis(trichloromethyl) carbonate
32315-10-9

bis(trichloromethyl) carbonate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

5,10-dioxa-6,9-dioxo-18,20-diazadecahydro[5]helicene

5,10-dioxa-6,9-dioxo-18,20-diazadecahydro[5]helicene

Conditions
ConditionsYield
With samarium; titanium tetrachloride In tetrahydrofuran for 2h; Reagent/catalyst; Temperature; Inert atmosphere; Reflux; diastereoselective reaction;88%
water
7732-18-5

water

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Zn(H2O)(C2H4(NCHC6H4O)2)
14897-25-7

Zn(H2O)(C2H4(NCHC6H4O)2)

Conditions
ConditionsYield
With tetrabutylammonium tetrafluoroborate In acetonitrile at 20℃; for 1.5h; Electrochemical reaction;88%
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

N,N'-ethylenebis(salicylideneiminato)iron(II)
578710-63-1, 14167-12-5

N,N'-ethylenebis(salicylideneiminato)iron(II)

Conditions
ConditionsYield
With tetrabutylammonium tetrafluoroborate In acetonitrile at 20℃; for 1.5h; Electrochemical reaction; Inert atmosphere;88%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

p-cresol
106-44-5

p-cresol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-methylphenolato)2]

[Ti(N,N’-ethylenebis(salicylideneiminate))(4-methylphenolato)2]

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;88%
Reaxys ID: 29769774

Reaxys ID: 29769774

water
7732-18-5

water

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

Mn2O2(OC6H4CHNCH2CH2NHCC6H4O)2
543689-39-0, 200950-95-4, 80786-75-0

Mn2O2(OC6H4CHNCH2CH2NHCC6H4O)2

Conditions
ConditionsYield
With tetrabutylammonium tetrafluoroborate In acetonitrile at 20℃; for 1.5h; Electrochemical reaction;87%
neodymium(III) chloride

neodymium(III) chloride

ethanol
64-17-5

ethanol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

C16H16N2O2*Nd(3+)*3Cl(1-)*2C2H6O

C16H16N2O2*Nd(3+)*3Cl(1-)*2C2H6O

Conditions
ConditionsYield
at 80℃; for 3h;86.3%
2,2,4,4,6,6-hexachloro-1,3,5-triaza-2,4,6-triphosphorine
940-71-6

2,2,4,4,6,6-hexachloro-1,3,5-triaza-2,4,6-triphosphorine

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

C48H42N9O6P3
1356329-92-4

C48H42N9O6P3

Conditions
ConditionsYield
With Al2O3/KOH In toluene at 25℃; for 2h; regiospecific reaction;86%
titanium(IV) isopropylate
546-68-9

titanium(IV) isopropylate

3-methyl-phenol
108-39-4

3-methyl-phenol

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[Ti(N,N’-ethylenebis(salicylideneiminate))(3-methylphenolato)2]

[Ti(N,N’-ethylenebis(salicylideneiminate))(3-methylphenolato)2]

Conditions
ConditionsYield
In dichloromethane at 20℃; for 0.166667h; Inert atmosphere;86%
methanol
67-56-1

methanol

uranyl acetate

uranyl acetate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

C17H17N2O5U

C17H17N2O5U

Conditions
ConditionsYield
for 3h; Reflux;85%
iron(III) chloride

iron(III) chloride

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[1,6-bis(2-hydroxyphenyl)-2,5-diaza-hexa-1,5-diene]iron(III) chloride
38586-93-5, 16649-19-7

[1,6-bis(2-hydroxyphenyl)-2,5-diaza-hexa-1,5-diene]iron(III) chloride

Conditions
ConditionsYield
In ethanol at 20℃; for 4h; Inert atmosphere;85%
In ethanol Reflux;76%
for 6h; pH=7; Reflux;
In methanol at 25℃; for 10h; Inert atmosphere;
With trimethylamine In methanol Inert atmosphere;
N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

salicylaldehyde
90-02-8

salicylaldehyde

Conditions
ConditionsYield
With zirconium hydrogen sulfate; silica gel In hexane for 2.8h; Heating;84%
With water In dimethyl sulfoxide for 0.5h; pH=7.4; Time;
manganese (II) acetate tetrahydrate
6156-78-1

manganese (II) acetate tetrahydrate

N,N'-ethylenebis(salicylideneimine)
94-93-9

N,N'-ethylenebis(salicylideneimine)

[((bis(salicylidene)ethylenediamine)(-2H))Mn(acetate)]
19478-47-8, 51436-86-3, 53318-90-4

[((bis(salicylidene)ethylenediamine)(-2H))Mn(acetate)]

Conditions
ConditionsYield
In ethanol for 2h; Reflux;83%

94-93-9Relevant articles and documents

Synthesis and spectral investigation (1H and 13C) of Tetradentate schiff base Ligands for the preparation of post transition bimetallic complexes of antimicrobial importance

Zahoor, Ameer Fawad,Yousaf, Muhammad,Pervaiz, Muhammad,Anjum, Anbreen,Ali, Kulsoom Ghulam,Zahid, Faisal Maqbool,Ahmad, Sajjad,Bukhari, Shazia Anwer,Parveen, Bushra

, p. 841 - 845 (2014)

A tetradentate Schiff base ligand 2-(bis-2-hydroxylphenylidene)-1,2- diiminoethanne (L) was synthesized and then its structure was investigated by 1H NMR and 13C NMR techniques. The ligand and its bimetallic complexes were screened in vitro for

Synthesis, characterization and catalytic activity of Fe(Salen) intercalated α-zirconium phosphate for the oxidation of cyclohexene

Khare, Savita,Chokhare, Rajendra

, p. 83 - 92 (2011)

Iron(III)-Salen intercalated α-zirconium phosphate, abbreviated as {α-ZrP·Fe(Salen)} was synthesized in situ by the flexible ligand method. The resulting compound was characterized by BET surface area, X-ray diffraction, scanning electron microscopy, ener

Synthesis, characterization and biological studies of bis-{μ-2,2'- [ethane-1,3-diylbis(nitrilomethylidyne)]diphenolato}dicopper(II) Using Triple Component Solvent System

Yousaf, Muhammad,Pervaiz, Muhammad,Zahoor, Ameer Fawad,Hussain, Abdullah Ijaz,Khosa, Muhammad Kaleem Khan,Ashraf, Sadia,Sagir, Muhammad,Ashar-Uz-Zaman,Shehzad, Khurram

, p. 521 - 524 (2013)

The bis-{μ-2,2'-[ethane-1,3-diyl-bis(nitrilomethylidyne)]diphenolato} dicopper(II) with the molecular formula [Cu2(C16H 14N2O2)2] shows the dimeric complex. Distorted square pyramidal geome

First examples of near-infrared luminescent poly(methyl methacrylate)-supported metallopolymers based on Zn2Ln-arrayed schiff base complexes

Miao, Tie-Zheng,Feng, Wei-Xu,Zhang, Zhao,Su, Pei-Yang,Lü, Xing-Qiang,Song, Ji-Rong,Fan, Dai-Di,Wong, Wai-Kwok,Jones, Richard A.,Su, Cheng-Yong

, p. 2839 - 2848 (2014)

The first examples of Wolf Type II Zn2Ln-containing metallopolymers poly{MMA-co-[Zn2(L)2(4-vp) 2Ln(NO3)3]} (Ln = La, Nd, Yb, Er, Gd; H 2L = N,N′-bis(salicylidene)ethylene-1,2-diamine; 4-vp = 4-vinylpyridine; MMA = methyl methacrylate) are obtained from the controlled copolymerization of heterotrinuclear Zn2Ln-arrayed complexes [Zn 2(L)2(4-vp)2Ln(NO3)3] (Ln = La, 1; Ln = Nd, 2; Ln = Yb, 3; Ln = Er, 4; Ln = Gd, 5) with MMA. The strong and characteristic near-infrared (NIR) luminescent Ln3+-centered emission for each of the PMMA-supported poly{MMA-co-[Zn2(L) 2(4-vp)2Ln(NO3)3]} (Ln = Nd, Yb, Er) hybrid materials is retained with somewhat higher intrinsic quantum yields than those of the respective Zn2Ln-arrayed complex. Especially for poly(MMA-co-3), which has more efficient sensitization from both ligand-centered singlet (1LC) and triplet (3LC) states of the chromophores, the concentration self-quenching of Yb3+-based NIR luminescence could be effectively prevented. The first examples of Wolf Type II near-infrared-luminescent Zn2Ln-containing metallopolymers poly{MMA-co-[Zn2(L)2(4-vp)2Ln(NO 3)3]} (H2L = N,N′-bis(salicylidene) ethylene-1,2-diamine; Ln = La, Nd, Yb, Er, Gd; MMA = methyl methacrylate; 4-vp = 4-vinylpridine) are obtained from the controlled copolymerization of MMA with a series of Zn2Ln-arrayed Schiff base complexes [Zn 2(L)2(4-vp)2Ln(NO3)3]. Copyright

C-C and C-H coupling reactions by Fe3O4/KCC-1/APTPOSS supported palladium-salen-bridged ionic networks as a reusable catalyst

Hassankhani, Asadollah,Sadeghzadeh, Seyed Mohsen,Zhiani, Rahele

, p. 8761 - 8769 (2018)

This study investigates the potential application of an efficient, easily recoverable and reusable magnetically separable Fe3O4/KCC-1/APTPOSS nanoparticle-supported salen/Pd(ii) catalyst for C-C and C-H cross-couplings. The Fe3O4/KCC-1/APTPOSS/salen/Pd(ii) MNPs were thoroughly characterized by using TEM, FE-SEM, TGA, XRD, VSM, FT-IR, ICP-MS, and BET. This observation was exploited in the direct and selective chemical reaction of 2-acetyl-benzaldehyde with cyclopentadiene for the synthesis of pentafulvene. The recycled catalyst has been analyzed by ICP-MS showing only minor changes in the morphology after the reaction, thus confirming the robustness of the catalyst.

Salen copper (II) complex encapsulated in y zeolite: An effective heterogeneous catalyst for TCF pulp bleaching using peracetic acid

Zhang, Na,Zhou, Xue-Fei

, p. 66 - 72 (2012)

Cu(salen) and NaY encapsulated complexes, were synthesized by the "impregnation" (Cu(salen)/Y-IM) and flexible ligand "ship-in-a-botttle" (Cu(salen)/Y-SB) method. The resulting compounds were characterized by XRD, FTIR, DR UV-vis, BET. The encapsulated co

Synthesis, crystal structures, and superoxide dismutase activity of two new multinuclear manganese(III)-salen-4,4′-bipyridine complexes

Deawati, Yusi,Onggo, Djulia,Mulyani, Irma,Hastiawan, Iwan,Kurnia, Dikdik,L?nnecke, Peter,Schmorl, Sara,Kersting, Berthold,Hey-Hawkins, Evamarie

, p. 353 - 357 (2018)

Manganese(III)-salen complexes have been reported as superoxide dismutase mimics (mSOD) that can scavenge superoxide anion radicals. They are mononuclear complexes with a variety of salen ligands. Here, two new multinuclear manganese(III)-salen complexes

Solution behaviour of (N,N'-ethylenebis(salicylideneiminato))- iron(III) chloride in aqueous methanol at 298.15, 303.15 and 313.15 K

Brahman, Dhiraj,Sinha, Biswajit

, p. 225 - 239 (2014)

In this study partial molar volumes (φ0v ) and viscosity B-coefficients of (N,N'-ethylene-bis(salicylideneiminato))iron(III) chloride, abbreviated as FeIII(salen)Cl, in different aqueous methanolic solutions were determine

Synthesis characterization and biological screening of tri-benzyltin(IV) complexes of some Schiff bases

Rehman, Wajid,Badshah, Amin,Baloch, Musa Kaleem,Ali, Saqib,Hameed, Gulzar,Khan, Khalid M.

, p. 929 - 934 (2004)

Synthesis and characterization of some novel di and tri-benzyltin(IV) complexes of some Schiff bases are reported. The 1H-NMR, 13C-NMR, 119Sn-NMR, IR, Elemental Analysis and 119Sn Moessauber studies are made for structural determination. Spectroscopic data reveals that the ligand molecule is bound to the tin atom through oxygen. On the basis of spectroscopic data tetrahedral geometry is proposed for the synthesized compounds. The synthesized compounds have been tested against various microorganisms. The results obtained show that the synthesized compounds have promising activity against all the tested micro-organisms.

Synthesis and characterization of bimetallic post transition complexes for antimicrobial activity

Pervaiz,Yousaf,Sagir,Mushtaq,Naz,Ullah,Mushtaq

, p. 546 - 552 (2015)

Antimicrobial and antibacterial activities of bimetallic complexes are very important in variety of biological mechanisms. In this research work, a Schiff base ligand 2-(bis-2-hydroxylphenylidene)-1,2-iminoethane was prepared by condensation reaction betw

A zig-zag end-to-end azido bridged MnIII 1-D coordination polymer: Spectral elucidation, magnetism, redox study and biological activity

Das, Kuheli,Datta, Amitabha,Beyene, Belete B.,Massera, Chiara,Garribba, Eugenio,Sinha, Chittaranjan,Akitsu, Takashiro,Tanka, Shinnosuke

, p. 315 - 322 (2017)

A zig-zag one-dimensional Mn(III) coordination polymer, {[C6H4(O)CHN(CH2)2NCH(O)C6H4]Mn(N3)}n (1) has been synthesized reacting a manganese salt with the Schiff base precursor H2L, obtained condensing salicyldehyde and ethylenediamine. The compound has been characterized by IR, UV–Vis and EPR spectroscopy. Single crystal X-ray diffraction studies have revealed that the Mn atom possesses a distorted octahedral environment and the metals connected by end-to-end azido ligands lead to the formation of 1-D zig-zag molecular chains. Temperature dependent magnetic studies have shown the presence of weak anti-ferromagnetic coupling among the Mn centers. Cyclic voltammetry has evidenced the presence of a reversible redox couple for the Mn3+/Mn2+ system. Both the ligand and complex 1 exhibit anti-mycobacterial activity and considerable efficacy on Mycobacterium tuberculosis H37Rv ATCC 27294 and M. tuberculosis H37Ra ATCC 25177 strains. The cytotoxicity study on different human cancer cell lines (Caco 2, MCF7 and A549) suggests that complex 1 has potential anticancer properties.

Synthesis, dft calculations, antiproliferative, bactericidal activity and molecular docking of novel mixed-ligand salen/8-hydroxyquinoline metal complexes

Abdalla, Ehab M.,Abdel Rahman, Laila H.,Al-Farhan, Badriah Saad,Basha, Maram T.,El-Ezz, Doaa Abou,El-Saghier, Ahmed M. M.,Marzouk, Adel A.,Shehata, Mohamed R.

, (2021/08/13)

Despite the common use of salens and hydroxyquinolines as therapeutic and bioactive agents, their metal complexes are still under development. Here, we report the synthesis of novel mixed-ligand metal complexes (MSQ) comprising salen (S), derived from (2,2′-{1,2-ethanediylbis [nitrilo(E) methylylidene]}diphenol, and 8-hydroxyquinoline (Q) with Co(II), Ni(II), Cd(II), Al(III), and La(III). The structures and properties of these MSQ metal complexes were investigated using molar conductivity, melting point, FTIR,1H NMR,13C NMR, UV–VIS, mass spectra, and thermal analysis. Quantum calculation, analytical, and experimental measurements seem to suggest the proposed structure of the compounds and its uncommon monobasic tridentate binding mode of salen via phenolic oxygen, azomethine group, and the NH group. The general molecular formula of MSQ metal complexes is [M(S)(Q)(H2O)] for M (II) = Co, Ni, and Cd or [M(S)(Q)(Cl)] and [M(S)(Q)(H2O)]Cl for M(III) = La and Al, respectively. Importantly, all prepared metal complexes were evaluated for their antimicrobial and anticancer activities. The metal complexes exhibited high cytotoxic potency against human breast cancer (MDA-MB231) and liver cancer (Hep-G2) cell lines. Among all MSQ metal complexes, CoSQ and LaSQ produced IC50 values (1.49 and 1.95 μM, respectively) that were comparable to that of cisplatin (1.55 μM) against Hep-G2 cells, whereas CdSQ and LaSQ had best potency against MDA-MB231 with IC50 values of 1.95 and 1.43 μM, respectively. Furthermore, the metal complexes exhibited significant antimicrobial activities against a wide spectrum of both Gram-positive and-negative bacterial and fungal strains. The antibacterial and antifungal efficacies for the MSQ metal complexes, the free S and Q ligands, and the standard drugs gentamycin and ketoconazole decreased in the order AlSQ > LaSQ > CdSQ > gentamycin > NiSQ > CoSQ > Q > S for antibacterial activity, and for antifungal activity followed the trend of LaSQ > AlSQ > CdSQ > ketoconazole > NiSQ > CoSQ > Q > S. Molecular docking studies were performed to investigate the binding of the synthesized compounds with breast cancer oxidoreductase (PDB ID: 3HB5). According to the data obtained, the most probable coordination geometry is octahedral for all the metal complexes. The molecular and electronic structures of the metal complexes were optimized theoretically, and their quantum chemical parameters were calculated. PXRD results for the Cd(II) and La(III) metal complexes indicated that they were crystalline in nature.

Synthesis, Characterization, Theoretical Studies, and Antimicrobial/Antitumor Potencies of Salen and Salen/Imidazole Complexes of Co (II), Ni (II), Cu (II), Cd (II), Al (III) and La (III)

Abdalla, Ehab M.,Abdel Rahman, Laila H.,Abdelhamid, Antar A.,Shehata, Mohamed R.,Alothman, Asma A.,Nafady, Ayman

, (2020/07/13)

Although salens and imidazoles are well-studied motifs among bioactive and therapeutic agents, their properties when combined in transition metal complexes are not well developed. To explore the structure/reactivity of this class of compounds, a salen-based ligand, namely (2,2′-{1,2-ethanediylbis[nitrilo(E)methylylidene]}diphenol, S), and its binary (MS) and ternary (MSI) complexes (I = imidazole; M = Co (II), Ni (II), Cu (II), Cd (II), Al (III), and La (III)) have been synthesized and fully characterized by standard physicochemical and theoretical methods. Evidence from structural analysis tools along with DFT modeling revealed an unusual monobasic tridentate salen binding mode, involving the phenolic oxygen, the nitrogen of the azomethine group, and NH group formed via phenol-to-cyclohexadienone tautomerization, giving rise to a general molecular formula of MSI complexes as [M(S)(I)2(Cl)] for M (II) = Co, Ni, Cu and Cd or [M(S)(I)(Cl)2] for M (III) = Al and La, respectively. The antimicrobial activities of S, MS, and MSI were screened against several bacterial and fungal strains. Of all tested complexes, CdS and CuSI were the most effective antimicrobials, giving larger inhibition zones than the reference antibiotics. The antimicrobial efficacy for the MS complexes follows the order: CdS > gentamicin > CuS > NiS > CoS > LaS > AlS > S, whereas MSI complex, potencies are ordered as CuSI > gentamicin > CdSI >NiSI > CoSI > LaSI > AlSI > S. In vitro cytotoxicity screening of MSI complexes disclosed that both CuSI and CdSI exhibited higher activity against human liver (Hep-G2) and breast (MDA-MB231) carcinoma cell lines than the reference (cisplatin) drug. The satisfactory bioactivities observed for several of these compounds supports the underlying design idea for combining important bioactive motifs for possible therapeutic benefit.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 94-93-9